ICCC · Immucell Corp /De/
Market Cap
$90.14M
Shares
9.08M
Volume · Oct 5
6113
Avg daily vol (3M)
24.24K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.75
Open$9.80
Day$9.61–9.80
52W close$4.56–11.72
Avg vol 30d15K
Short int20K · 0.2% float · 1.6d
Short vol18%
Last earningsAug 14, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 13, 2026
Est · unconfirmed
· in 1 wks
filed Aug 13, 2026
call held Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+48.9%
Trailing year
Short interest
0.2%
Latest settlement · 1.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+15%
above
Price vs 50-day avg
−5%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+37%
trailing
YTD return
+59%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.22% of float · ▲ +2.9% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Squeeze score
31
low risk · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
43%
contracting
EPS growth
+54%
Y/Y
Free cash flow
$1.2M
Valuation
P/E 141.8
rich
Balance sheet
$5.3M
net debt
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
3.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 14, 2026
initial phase of the expansion
Freeze-drying capacity investment
$3.5M
phase is expected to be completed by the end of 2027
Liquids processing capacity investment
$4.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+15%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.22% of float · ▲ +2.9% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $10 · 72%
Range high $12
vs 200-day avg +15%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.7M | the three months ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 1.84M
+46K Income tax expense
+92K Interest expense (excluding debt issuance and debt discount costs)
+471K Depreciation
+3K Amortization (including debt issuance and debt discount costs)
+240K Stock-based compensation expense
= Adjusted EBITDA 2.69M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICCC
this stock
Immucell Corp /De/
|
$90.14M | +58.5% | +51.6% | 141.8 | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICCC | -1.8% | -2.5% | +37.1% | -0.5% | +58.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.5% | -2.0% | +25.0% | -1.4% | +45.7% |